Perfluorocarbon-based oxygen carriers: Review of products and trials

Artificial Organs

Volumn 34, Issue 8, 2010, Pages 622-634

  Castro, Camila Irene ^a   Briceno, Juan Carlos ^a  

^a UNIVERSIDAD DE LOS ANDES   (Colombia)

Author keywords

Blood substitutes; Clinical trials; Clinical use; Emulsions; Perfluorocarbons; Preclinical studies

Indexed keywords

OXYGEN;

CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CLINICAL USE; HIGH SOLUBILITY; HUMAN USE; OXYGEN CARRIER; PERFLUOROCARBONS; PRECLINICAL STUDIES;

BLOOD;

AF 0144; COLUMBIAN EMULSION; FLUOSOL DA; FRENCH EMULSION; FTOROSAN; OXYCYTE; OXYFLUOR; PERFLUOROCARBON BASED OXYGEN CARRIER; PERFLUOROOCTYL BROMIDE; PERFLUOROTRIBUTYLAMINE; PERFTORAN; PLASMA SUBSTITUTE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AIR EMBOLISM; ALCOHOL WITHDRAWAL; ANEMIA; ANTICOAGULATION; ATHEROSCLEROSIS; BLEEDING; BRAIN HYPOXIA; BRAIN INJURY; BRAIN ISCHEMIA; CARBON MONOXIDE INTOXICATION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DECOMPRESSION SICKNESS; DRUG FORMULATION; EMULSION; HEART INFARCTION; HEART SURGERY; HEMODILUTION; HEMORRHAGIC SHOCK; HEPATITIS; HUMAN; IMMUNITY; INFLAMMATION; ISCHEMIA; ISOLATED HEART; LIVER TRANSPLANTATION; LUNG INJURY; MEDLINE; NONHUMAN; ORTHOPEDIC SURGERY; PERITONITIS; PHLEGMON; PRIORITY JOURNAL; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT FAILURE; VALVULOPLASTY; VASODILATATION; XENOTRANSPLANTATION;

EID: 77955443024     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2009.00944.x     Document Type: Review

References (92)

1. Nosé Y. Is there a role for blood substitutes in civilian medicine: a drug for emergency shock cases? Artif Organs 2004 28 : 807 812.
2. Yoshiba F, Kawaguchi AT, Hyodo O, Kinoue T, Inokuchi S, Kato S. Possible role of artificial oxygen carriers in transfusion medicine: a retrospective analysis on the current transfusion practice. Artif Organs 2009 33 : 127 132.
3. Riess JG. Blood substitutes: fluorocarbon approach. In : Swarbrick J, ed. Encyclopedia of Pharmaceutical Technology, 3rd Edition. New York : Informa Healthcare, 2007 336.
4. Winslow RM. Historical background. In : Winslow RM, ed. Blood Substitutes. London : London Academic Press, 2006 5 16.
5. Riess JG. Oxygen carriers ("blood substitutes") raison d'être, chemistry, and some physiology. Chem Rev 2001 101 : 2797 2920.
6. Ness PM, Cushing MM. Oxygen therapeutics: pursuit of an alternative to the donor red blood cell. Arch Pathol Lab Med 2007 131 : 734 741.
7. Kawaguchi AT. Artificial oxygen carriers: a clinical point of view. Artif Organs 2009 33 : 97 9.
8. Simoni J, Villanueva-Meyer J, Simoni G, Moeller JF, Wesson DE. Control of oxidative reactions of hemoglobin in the design of blood substitutes: role of the ascorbate-glutathione antioxidant system. Artif Organs 2009 33 : 115 126.
9. Estep T, Bucci E, Farmer M, et al. Basic science focus on blood substitutes: a summary of the NHLBI Division of Blood Diseases and Resources Working Group Workshop, March 1, 2006. Transfusion 2008 48 : 776 782.
10. Winslow RM. Current status of oxygen carriers ("blood substitutes"): 2006. Vox Sang 2006 91 : 102 110.
11. Lane TA. Perfluorochemical-based artificial oxygen carrying red cell substitutes. Transfus Sci 1995 16 : 19 31.
12. Habler OP, Messmer KF. Tissue perfusion and oxygenation with blood substitutes. Adv Drug Deliv Rev 2000 40 : 171 184.
13. Clark LC, Jr., Gollan F. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science 1966 152 : 1755 1756.
14. Lowe KC. Perfluorinated blood substitutes and artificial oxygen carriers. Blood Rev 1999 13 : 171 184.
15. Riess JG. Blood substitutes: fluorocarbon approach. In : Swarbrick J, ed. Encyclopedia of Pharmaceutical Technology, 3rd Edition. New York : Informa Healthcare, 2007 345.
16. Wakasa T, Kawai N, Yanagi Y, Hayase Y, Kishi K. A study of hypoxic cell radiosensitizer applied to Ehrlich ascite tumour: a comparison of FC43 emulsion and pentoxyfilline. Br J Radiol 2002 75 : 909 912.
17. Millard RW. Oxygen solubility, rheology and hemodynamics of perfluorocarbon emulsion blood substitutes. Artif Cells Blood Substit Immobil Biotechnol 1994 22 : 235 244.
18. Faithfull NS. Mechanisms and efficacy of fluorochemical oxygen transport and delivery. Artif Cells Blood Substit Immobil Biotechnol 1994 22 : 181 197.
19. Durnovo EA, Furman IV, Pushkin SY, Maslennikov IA, Bondar OG, Ivanitsky GR. Clinical results of the application of perftoran for the treatment of odontogenous abcesses and phlegmons in the maxillofacial region. J Craniomaxillofac Surg 2008 36 : 161 172.
20. Perftoran. About "PERFTORAN Available at: http://perftoran.ru/Eng/ content/view/22/55/. Accessed June 6, 2008.
21. Eckmann DM, Lomivorotov VN. Microvascular gas embolization clearance following perfluorocarbon administration. J Appl Physiol 2003 94 : 860 868.
22. Riess JG. Perfluorocarbon-based oxygen delivery. Artif Cells Blood Substit Immobil Biotechnol 2006 34 : 567 580.
23. Riess JG, Krafft MP. Fluorocarbon emulsions as in vivo oxygen delivery systems: background and chemistry. In : Winslow RM, ed. Blood Substitutes. London : Academic Press, 2006 259 275.
24. Cuignet OY, Wood BL, Chandler WL, Spiess BD. A second-generation blood substitute (Perfluorodichlorooctane emulsion) generates spurious elevations in platelet counts from automated hematology analyzers. Anesth Analg 2000 90 : 517 522.
25. Remy B, Deby-Dupont G, Lamy M. Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions. Br Med Bull 1999 55 : 277 298.
26. Goodin TH, Grossbard EB, Kaufman RJ, et al. A perfluorochemical emulsion for prehospital resuscitation of experimental hemorrhagic shock: a prospective, randomized, controlled study. Crit Care Med 1994 22 : 680 689.
27. Cabrales P, Tsai AG, Frangos JA, Briceno JC, Intaglietta M. Oxygen delivery and consumption in the microcirculation after extreme hemodilution with perfluorocarbons. Am J Physiol Heart Circ Physiol 2004 287 : H320 30.
28. Cabrales P, Tsai AG, Intaglietta M. Perfluorocarbon in microcirculation during ischemia reperfusion. J Am Coll Surg 2007 204 : 225 235.
29. Gardeazabal T, Cabrera M, Cabrales P, Intaglietta M, Briceno JC. Oxygen transport during hemodilution with a perfluorocarbon-based oxygen carrier: effect of altitude and hyperoxia. J Appl Physiol 2008 105 : 588 594.
30. Nader ND, Knight PR, Davidson BA, Safaee SS, Steinhorn DM. Systemic perfluorocarbons suppress the acute lung inflammation after gastric acid aspiration in rats. Anesth Analg 2000 90 : 356 361.
31. Gould SA, Rosen AL, Sehgal LR, et al. Fluosol-DA as a red-cell substitute in acute anemia. N Engl J Med 1986 314 : 1653 1656.
32. Spence RK, McCoy S, Costabile J, et al. Fluosol DA-20 in the treatment of severe anemia: randomized, controlled study of 46 patients. Crit Care Med 1990 18 : 1227 1230.
33. Young LH, Jaffe CC, Revkin JH, McNulty PH, Cleman M. Metabolic and functional effects of perfluorocarbon distal perfusion during coronary angioplasty. Am J Cardiol 1990 65 : 986 990.
34. von der Hardt K, Kandler MA, Brenn G, et al. Comparison of aerosol therapy with different perfluorocarbons in surfactant-depleted animals. Crit Care Med 2004 32 : 1200 1206.
35. Southworth R, Blackburn SC, Davey KA, Sharland GK, Garlick PB. The low oxygen-carrying capacity of Krebs buffer causes a doubling in ventricular wall thickness in the isolated heart. Can J Physiol Pharmacol 2005 83 : 174 182.
36. Bito A, Inoue K, Asano M, Ando S, Takaba T. Experimental myocardial preservation study of adding perfluorochemicals (FC43) in lidocaine cardioplegia. Jpn J Thorac Cardiovasc Surg 2000 48 : 280 290.
37. Tanaka M. Mechanisms of rejection in guinea pig (GP)-to-rat liver xenotransplantation: improvement of recoloration of GP liver graft and effects of perfluorochemical (FC43) in GP-to-rat liver xenotransplantation Hokkaido Igaku Zasshi 1999 74 : 441 455.
38. Eckmann DM, Armstead SC. Influence of endothelial glycocalyx degradation and surfactants on air embolism adhesion. Anesthesiology 2006 105 : 1220 1227.
39. Kozhura VL, Basarab DA, Timkina MI, Golubev AM, Reshetnyak VI, Moroz VV. Reperfusion injury after critical intestinal ischemia and its correction with perfluorochemical emulsion "perftoran World J Gastroenterol 2005 11 : 7084 7090.
40. Lykova OF, Romanova TV, Moiseeva LM, Konysheva TV, Grigor'ev EV, Zorin NA. Effect of perftoran on macroglobulin content in the plasma and peritoneal exudate of rats with acute exudative inflammation (peritonitis). Bull Exp Biol Med 2004 138 : 351 353.
41. Miskevich D, Petushok N, Gerasimchik P, Borodinskii A. Effect of Perftoran on free radical homeostasis during alcohol withdrawal syndrome. Bull Exp Biol Med 2007 143 : 43 5.
42. Leskova GF, Michunskaya AB, Kobozeva LP, Klimenko ED. Influence of perftoran on structural and metabolic disturbances in the liver during experimental atherosclerosis. Bull Exp Biol Med 2003 136 : 340 343.
43. Kovelenov AY, Mikhal'tsov AN, Malkov AN. Perftoran as a means modulating the functional activity of liver macrophages. Bull Exp Biol Med 2002 134 : 551 553.
44. Verdin-Vasquez R, Zepeda-Perez C, Ferra-Ferrer R, Chavez-Negrete A, Contreras F, Barroso-Aranda J. Use of perftoran emulsion to decrease allogeneic blood transfusion in cardiac surgery: clinical trial. Artif Cells Blood Substit Immobil Biotechnol 2006 34 : 433 454.
45. Paxian M, Keller SA, Huynh TT, Clemens MG. Perflubron emulsion improves hepatic microvascular integrity and mitochondrial redox state after hemorrhagic shock. Shock 2003 20 : 449 457.
46. Gale SC, Gorman GD, Copeland JG, McDonagh PF. Perflubron emulsion prevents PMN activation and improves myocardial functional recovery after cold ischemia and reperfusion. J Surg Res 2007 138 : 135 140.
47. Daugherty WP, Levasseur JE, Sun D, Spiess BD, Bullock MR. Perfluorocarbon emulsion improves cerebral oxygenation and mitochondrial function after fluid percussion brain injury in rats. Neurosurgery 2004 54 : 1223 1230. discussion 1230.
48. Rempf C, Standl T, Gottschalk A, et al. Effects of a prophylactic or therapeutic application of perflubron emulsion on myocardial ischaemia-reperfusion injury in rats. Eur J Anaesthesiol 2008 25 : 850 859.
49. Dainer H, Nelson J, Brass K, Montcalm-Smith E, Mahon R. Short oxygen prebreathing and intravenous perfluorocarbon emulsion reduces morbidity and mortality in a swine saturation model of decompression sickness. J Appl Physiol 2007 102 : 1099 1104.
50. Leese PT, Noveck RJ, Shorr JS, Woods CM, Flaim KE, Keipert PE. Randomized safety studies of intravenous perflubron emulsion. I. Effects on coagulation function in healthy volunteers. Anesth Analg 2000 91 : 804 811.
51. Noveck RJ, Shannon EJ, Leese PT, et al. Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers. Anesth Analg 2000 91 : 812 822.
52. Spahn DR, van Brempt R, Theilmeier G, et al. Perflubron emulsion delays blood transfusions in orthopedic surgery. European Perflubron Emulsion Study Group. Anesthesiology 1999 91 : 1195 1208.
53. Spahn DR, Waschke KF, Standl T, et al. Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: results of a European phase 3 study. Anesthesiology 2002 97 : 1338 1349.
54. Frumento RJ, Mongero L, Naka Y, Bennett-Guerrero E. Preserved gastric tonometric variables in cardiac surgical patients administered intravenous perflubron emulsion. Anesth Analg 2002 94 : 809 814.
55. Briceño JC, Rincón IE, Vélez JF, Castro I, Arcos MI, Velásquez CE. Oxygen transport and consumption during experimental cardiopulmonary bypass using oxyfluor. ASAIO J 1999 45 : 322 327.
56. Yang Z-J, Price CD, Bosco G, et al. The effect of isovolemic hemodilution with Oxycyte, a perfluorocarbon emulsion, on cerebral blood flow in rats. PLoS ONE 2008 3 : e2010.
57. Woitzik J, Schilling L. A new method for superselective middle cerebral artery infusion in the rat. J Neurosurg 2007 106 : 872 878.
58. Zhou Z, Sun D, Levasseur JE, et al. Perfluorocarbon emulsions improve cognitive recovery after lateral fluid percussion brain injury in rats. Neurosurgery 2008 63 : 799 806. discussion 806-7.
59. Oxygen Biotherapeutics Inc. Oxygen Biotherapeutics, Inc. Current Clinical Trials. Available at: http://www.oxybiomed.com/c-clinictrials.htm. Accessed October 5, 2009.
60. Oxygen Biotherapeutics Inc. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/results?term=oxycyte. Accessed July 05, 2009.
61. Audonnet-Blaise S, Krafft MP, Smani Y, et al. Resuscitation of severe but brief haemorrhagic shock with PFC in rabbits restores skeletal muscle oxygen delivery and does not alter skeletal muscle metabolism. Resuscitation 2006 70 : 124 132.
62. Tremper KK, Friedman AE, Levine EM, Lapin R, Camarillo D. The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol-DA. N Engl J Med 1982 307 : 277 283.
63. Spahn DR. Current status of artificial oxygen carriers. Adv Drug Deliv Rev 2000 40 : 143 151.
64. Jahr JS, Walker V, Manoochehri K. Blood substitutes as pharmacotherapies in clinical practice. Curr Opin Anesthesiol 2007 20 : 325 330. 10.1097/ACO.0b013e328172225a.
65. Ochikubo H, Wada S, Sugawara Y, Sueda T, Matsuura Y. Effect of FC43se on endotoxin-induced disseminated intravascular coagulation in rats. Hiroshima J Med Sci 1999 48 : 71 7.
66. Yarema IV, Magomedov MA. Experimental study of the use of perftoran for preventing the formation of postoperative adhesions in peritonitis. Bull Exp Biol Med 2003 136 : 582 584.
67. Kuznetsova IN. Perfluorocarbon emulsions stability in vitro and in vivo a review. Pharma Chem 2003 37 : 415 420.
68. Habler OP, Kleen MS, Hutter JW, et al. Hemodilution and intravenous perflubron emulsion as an alternative to blood transfusion: effects on tissue oxygenation during profound hemodilution in anesthetized dogs. Transfusion 1998 38 : 145 155.
69. Habler OP, Kleen MS, Hutter JW, et al. Effects of hyperoxic ventilation on hemodilution-induced changes in anesthetized dogs. Transfusion 1998 38 : 135 144.
70. Keipert PE, Faithfull NS, Bradley JD, et al. Enhanced oxygen delivery by perflubron emulsion during acute hemodilution. Artif Cells Blood Substit Immobil Biotechnol 1994 22 : 1161 1167.
71. Habler O, Kleen M, Hutter J, et al. IV perflubron emulsion versus autologous transfusion in severe normovolemic anemia: effects on left ventricular perfusion and function. Res Exp Med (Berl) 1998 197 : 301 318.
72. Nolte D, Pickelmann S, Lang M, Keipert P, Messmer K. Compatibility of different colloid plasma expanders with perflubron emulsion: an intravital microscopic study in the hamster. Anesthesiology 2000 93 : 1261 1270.
73. Symons JD, Sun X, Flaim SF, del Balzo U. Perflubron emulsion improves tolerance to low-flow ischemia in isolated rabbit hearts. J Cardiovasc Pharmacol 1999 34 : 108 115.
74. Paxian M, Rensing H, Geckeis K, et al. Perflubron emulsion in prolonged hemorrhagic shock: influence on hepatocellular energy metabolism and oxygen-dependent gene expression. Anesthesiology 2003 98 : 1391 1399.
75. Rosen NA, Hopf HW, Hunt TK. Perflubron emulsion increases subcutaneous tissue oxygen tension in rats. Wound Repair Regen 2006 14 : 55 60.
76. Hill SE, Leone BJ, Faithfull NS, Flaim KE, Keipert PE, Newman MF. Perflubron emulsion (AF0144) augments harvesting of autologous blood: a phase II study in cardiac surgery. J Cardiothorac Vasc Anesth 2002 16 : 555 560.
77. Hill SE, Grocott HP, Leone BJ, White WD, Newman MF. Cerebral physiology of cardiac surgical patients treated with the perfluorocarbon emulsion, AF0144. Ann Thorac Surg 2005 80 : 1401 1407.
78. Mattrey RF. Are cerebral emboli real when perfluorocarbon emulsion (af0144) is used in cardiac surgery? Ann Thorac Surg 2007 83 : 1922 1923.
79. Hill SE, Grocott HP. Reply. Ann Thorac Surg 2007 83 : 1923.
80. Thyes C, Spahn DR. Current status of artificial O2 carriers. Anesthesiol Clin North America 2005 23 : 373 389. viii.
81. Riess JG. Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery. Artif Cells Blood Substit Immobil Biotechnol 2005 33 : 47 63.
82. Kim HW, Greenburg AG. Artificial oxygen carriers as red blood cell substitutes: a selected review and current status. Artificial Organs 2004 28 : 813 828.
83. Stowell C. Blood substitutes: time for a deep breath. Transfusion 2008 48 : 574 575.
84. Winslow RM. Blood substitutes. Adv Drug Deliv Rev 2000 40 : 131 142.
85. US-FDA. Guidance for industry: criteria for safety and efficacy evaluation of oxygen therapeutics as red blood cell substitutes. Available at: http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm074920.htm. Accessed July 13, 2009.
86. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 2008 299 : 2304 2312.
87. Levien LJ, Hodgson RE, James MF. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA 2008 1295 300 : 1298 1299, author reply.
88. Keipert PE, Olofsson C, Winslow RM. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA 2008 300 : 1295 1296, author reply 1298-9.
89. Lewis RJ, Fost N. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA 2008 1296 300 : 1298 1299, author reply.
90. Shander A, Javidroozi M, Thompson G. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA 2008 300 : 1296 1297, author reply 1298-9.
91. Sauaia A, Moore EE, Banerjee A. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA 2008 1297 300 : 1298 1299, author reply.
92. Sarani B, Gracias V. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA 2008 300 : 1297 1298, author reply 1298-9.